SAN DIEGO, April 26, 2018 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2018, before the opening of trading on Thursday, May 3, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, May 3. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (323) 794-2567 (preferred), or (888) 278-8469 (toll-free), and reference confirmation code 1443635. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 1443635. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, including antiviral and antifungal candidates in clinical development. Additional information on Vical is available at www.vical.com.
| Contact: | Andrew Hopkins |
| (858) 646-1127 | |
| Website: www.vical.com |


Nvidia Options Price in $280 Billion Earnings Swing
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake
OpenAI AI Agent Swarm Behind Hugging Face Hack
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Mercer International Stock Surges 45% on C$20 Million Canada Funding
SK Hynix Shares Fall as Workers Reject Wage Deal
Tesla Raises Cybertruck Prices by $5,000 in US
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 



